Figure 3.
Simulated plasma concentration versus time curves of AT‐RvD1 in NOD/ShiLtJ mice and humans. AT‐RvD1 was administered intravenously at 0.1 mg/kg for the simulations (n = 100 in each species). AT‐RvD1, aspirin‐triggered resolvin D1
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.